+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07472868

Comparing Neoadjuvant FOLFOXIRI Versus CAPOXFOLFOX Chemotherapy with Chemoradiotherapy Followed by Surgery or Watch-and-Wait in High-Risk Locally Advanced Rectal Cancer

Led by J. W. A. Burger · Updated on 2026-10-27

394

Participants Needed

20

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

The trial investigates treatments for patients with high-risk locally advanced rectal cancer. It compares triplet induction chemotherapy FOLFOXIRI with doublet induction chemotherapy CAPOXFOLFOX, both followed by chemoradiotherapy and then either surgery or a watch-and-wait approach. The study aims to find out if the triplet therapy leads to higher complete response rates, better quality of life, and improved long-term outcomes despite a potential increase in side effects. Participants in one group receive FOLFOXIRI chemotherapy given in cycles every two weeks, followed by chemoradiotherapy that includes radiation combined with capecitabine or an alternative drug if needed. The other group receives CAPOX or FOLFOX chemotherapy followed by the same chemoradiotherapy regimen. After these treatments, patients either have surgery or enter a watch-and-wait follow-up if their cancer shows complete response. Imaging scans are done at multiple points to evaluate treatment response, and surgery timing depends on these results. During the study, participants undergo regular imaging with MRI and CT scans, endoscopies, and clinical exams to assess tumor response. Quality of life and work productivity questionnaires are completed at baseline and after treatments. Researchers monitor treatment toxicity, dose adjustments, surgical outcomes, and long-term survival and recurrence over several years. Follow-up includes close monitoring for tumor regrowth or recurrence, especially for those in the watch-and-wait group, with visits scheduled up to five years after treatment.

CONDITIONS

Brief Title

Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

Research Team

M

Maaike M Borg, Drs.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here